Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Safety and efficacy of different lanreotide doses for polycystic liver disease

This month's issue of the Alimentary Pharmacology & Therapeutics investigates the safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease.

News image

Long-acting lanreotide 120 mg every 4 weeks reduces liver volume in patients with polycystic liver diseases.

Animal studies that demonstrated that the inhibition of hepatic and renal cystogenesis is dose dependent.

Dr Temmerman and colleagues from Belgium investigated the safety and efficacy of two different LAN doses in polycystic liver diseases patients.

The 6-month results of the LOCKCYST I trial, its extension study, and the LOCKCYST II trial were pooled.

Long-acting lanreotide at baseline and month 6 was measured by CT-scan and blindly re-analyzed by 2 independent radiologists.

Severe side effects with long-acting lanreotide 120 mg was 16%
Alimentary Pharmacology & Therapeutics

The study population consisted of 3 groups.

Each received treatment every 4 weeks during 6 months plus placebo, or long-acting lanreotide at 90 mg or 120 mg.

The team reported excellent inter-observer variability and agreement in the calculation of Long-acting lanreotide.

The researchers observed that severe side effects with placebo, long-acting lanreotide 90 mg and 120 mg were 0%, 7% and 16%, respectively.

Change in long-acting lanreotide after 6 months in these 3 groups included an increase of +36 mL, decrease of −82 mL, and decrease of -123 mL, respecitvely.

Based on ROC analysis, a reduction of 120 mL or more in liver volume has a positive predictive value of 64% for improving symptoms.

Dr Temmerman's team concludes, "Both long-acting lanreotide 90 mg and long-acting lanreotide120 mg reduce liver volume."

"Long-acting lanreotide 90 mg has less side effects. "

"This suggests that in case of intolerance to long-acting lanreotide 120 mg, a dose reduction to long-acting lanreotide 90 mg is meaningful."

Aliment Pharmacol Ther 2013: 38(4): 397–406
06 August 2013

Go to top of page Email this page Email this page to a colleague

 07 July 2015

Advanced search
 07 July 2015 
Fecal transplantation for ulcerative colitis
 07 July 2015 
Obesity and risk of hepatocellular carcinoma
 07 July 2015 
Anastomotic leak after elective surgery for colonic cancer
 06 July 2015 
Future colorectal surgery for metachronous cancers
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Health care use by IBD children
 02 July 2015 
Anastomotic leak and cancer cancer
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 29 June 2015 
Rescue therapy in ulcerative colitis
 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 25 June 2015 
Fecal microbiota in pediatric IBD
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 24 June 2015 
Environmental risk in IBD
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
NAFLD risk in celiac disease
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us